Recursion Named to Fast Company’s Annual List of the World’s Most Innovative Companies

SALT LAKE CITY–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/AI?src=hash” target=”_blank”gt;#AIlt;/agt;–Recursion,
a clinical-stage biotechnology company that combines artificial
intelligence (AI), experimental biology, and automation to discover and
develop drugs at scale, has been named to Fast Company’s
annual list of the World’s Most Innovative Companies for 2019. The list
honors the businesses making the most profound impact on both industry
and culture, showcasing a variety of ways to thrive in today’s volatile
world. Founded in 2013, Recursion is an industry leader in applying AI
to drug discovery and has created an innovative culture that brings
together data science, engineering and drug discovery teams. The company
has already achieved partnerships with leading pharmaceutical companies
such as Sanofi and Takeda and has advanced two programs into clinical
development.

“Our ability to innovate is directly tied to the strength of our
interdisciplinary teams. We’ve been able to bring together engineers,
biologists, data scientists, and chemists to build the most advanced
drug discovery teams in the industry,” said Chris Gibson, Ph.D.,
co-founder and CEO of Recursion. “They are working side-by-side to
reimagine the drug discovery process from start to finish and they
continue to find potential medicines for dozens of human conditions.”

Recursion has captured the attention of the biopharma industry with its
unique approach to AI-enabled drug discovery. The company has built an
unparalleled, high-dimensional dataset, designed for machine learning
(ML), with over 1.5 petabytes of biological images. It generates this
data through the “industrialization” of discovery biology, using
robotics and automation to run hundreds of thousands of experiments each
week, testing myriad biological perturbations on a range of disease
models in real human cells (everything from monogenic loss-of-function
conditions to complex inflammatory diseases). Recursion then captures
and analyzes the subtle cellular changes that take place through a
proprietary computer vision and data analysis stack that includes neural
networks.

“We’re capturing more than two million cellular images every week across
human genetics, immunology, inflammation, and other areas to create a
high-resolution map of human biology,” said Ron Alfa, M.D., Ph.D.,
Senior Vice President of Translational Discovery and Chief Evangelist.
“This map can help us significantly increase the speed and decrease the
cost of discovery biology, which is great for our partners and for our
own internal therapeutic programs.”

The World’s Most Innovative Companies is Fast Company’s signature
franchise and one of its most highly anticipated editorial efforts of
the year. It provides both a snapshot and a road map for the future of
innovation across the most dynamic sectors of the economy. Fast
Company
’s Most Innovative Companies issue (March-April
2019) is now available online at https://www.fastcompany.com/MIC,
as well as in app form via iTunes and on newsstands beginning February
27th. The hashtag is #fcmostinnovative.

About Recursion

Recursion is a clinical-stage biotechnology company combining
experimental biology and automation with artificial intelligence in a
massively parallel system to efficiently discover potential drugs for
diverse indications, including genetic disease, inflammation,
immunology, and infectious disease. Recursion applies causative
perturbations to human cells to generate disease models and associated
biological image data. Recursion’s rich, relatable database of more than
a petabyte of biological images generated in-house on the company’s
robotics platform enables advanced machine learning approaches to reveal
drug candidates, mechanisms of action, and potential toxicity, with the
eventual goal of decoding biology and advancing new therapeutics to
radically improve lives. Recursion is headquartered in Salt Lake City.
Learn more at www.recursionpharma.com,
or connect on Twitter,
Facebook,
and LinkedIn.

Contacts

Jessica Yingling, Ph.D.
Little
Dog Communications Inc
.
+1.858.344.8091
[email protected]

error: Content is protected !!